Form 4: NEOGENOMICS CEO Zook Receives Significant Equity Grants

NEOGENOMICS CEO Anthony P. Zook was granted 675,676 stock options and 406,918 restricted stock units effective March 1, 2026, as part of his compensation.

Summary

• Anthony P. Zook, Chief Executive Officer and Director of NEOGENOMICS INC, was granted significant equity awards.
• Effective March 1, 2026, Mr. Zook received 675,676 stock options with an exercise price of $10.81, which will vest ratably over the first three anniversary dates of the grant date.
• Also effective March 1, 2026, Mr. Zook was granted 406,918 restricted stock units (RSUs), which will vest ratably over the first three anniversary dates of the grant date.
• The stock options granted on March 1, 2026, are premium-price options, calculated at 110% of the closing price on February 27, 2026.
• Mr. Zook also holds previously granted stock options and RSUs, including 729,927 stock options and 421,496 restricted stock units granted on April 1, 2025, which also vest ratably over three years.
• His direct beneficial ownership of common stock is 38,066 shares, with an additional 18,900 shares held indirectly through the Amended and Restated Anthony P. Zook Living Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting continued executive alignment with shareholder interests through long-term equity incentives, which is a standard and generally healthy corporate governance practice.

Positives

• The significant equity grants align the CEO's long-term financial interests directly with the company's stock performance and shareholder value creation.
• The inclusion of premium-price options incentivizes substantial stock price appreciation, as the stock must rise above $10.81 for the March 1, 2026 options to be in-the-money.
• These grants demonstrate the company's commitment to retaining and incentivizing key executive leadership.

Negatives

• The vesting and eventual exercise of these stock options and restricted stock units could lead to future dilution for existing shareholders.

Risks

• No specific risks related to company operations, financial health, or strategic initiatives are detailed in this Form 4 filing.

Future Outlook

The grants of stock options and restricted stock units are structured with multi-year vesting schedules, specifically ratably over the first three anniversary dates of the grant date (March 1, 2026, and April 1, 2025). This indicates a long-term incentive structure for the CEO, aligning future compensation with sustained company performance over the next several years.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as stock options and restricted stock units, is a standard practice in the biotechnology and diagnostics industry for executive remuneration. This approach aims to align executive incentives with shareholder interests by tying a significant portion of compensation to the company's stock performance.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of these grants, including multi-year vesting and premium-priced options, is consistent with common executive compensation practices in the U.S. public markets, particularly within the life sciences sector.
• Similar long-term incentive plans are seen at companies like Exact Sciences Corp. (EXAS) or Guardant Health, Inc. (GH), where executive compensation packages often include substantial equity components designed to incentivize long-term value creation and retention.
• The premium-price options are a less common but effective mechanism to further align executive performance with significant stock appreciation, requiring the stock to outperform a set threshold before the options become profitable.

Stakeholder Impact

• Shareholders: Potential for future dilution as options and RSUs vest and are exercised; however, the grants aim to align CEO performance with shareholder value creation.
• Management: The CEO's compensation package is enhanced, providing long-term incentives tied to company performance.

Next Steps

• Vesting of 675,676 stock options on the first, second, and third anniversary dates of March 1, 2026.
• Vesting of 406,918 restricted stock units on the first, second, and third anniversary dates of March 1, 2026.
• Continued vesting of previously granted stock options and restricted stock units from April 1, 2025, and other dates.

Key Dates

Recommendation

This Form 4 filing primarily reports executive compensation grants, which are a routine aspect of corporate governance. While the grants align the CEO's interests with long-term shareholder value, this filing alone does not provide sufficient information regarding the company's operational performance, financial health, or strategic direction to warrant a 'buy' or 'sell' recommendation. Investors should consider this information in the broader context of NEOGENOMICS INC's overall financial reports and market position.

Keywords

NEOGENOMICS, NEO, Anthony Zook, CEO compensation, stock options, restricted stock units, equity grants, insider transaction, Form 4, executive compensation